Results 91 to 100 of about 19,166 (184)

The Relationship between the complement system and subclinical carotid atherosclerosis in patients with rheumatoid arthritis

Arthritis Research & Therapy
Background Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) events and CV mortality. Subclinical carotid atherosclerosis is independently associated with rates of incident CV events among patients with RA.
Marta Hernández-Díaz, Dara Rodríguez-González, Elena Heras-Recuero, Fuensanta Gómez-Bernal, Juan Carlos Quevedo-Abeledo, Agustín F. González-Rivero, Elena González-López, J. Gonzalo Ocejo-Vinyals, Alejandro Jimenez-Sosa, Miguel Ángel González-Gay, Iván Ferraz-Amaro   +10 more
doaj   +1 more source

A comparative analysis of cowpox virus (CPV WT) and a deletion mutant lacking the gene encoding the inflammation modulatory protein (CPV IMP)

, 2007
Includes bibliographical references (leaves 96-114).Cowpox virus has been found to encode the inflammation modulatory protein (IMP) (Miller, C.G., 1997), a homologue vaccinia virus complement control protein (VCP). VCP belongs to regulation of complement
Paulsen, Janis
core  

FcRn Inhibitor Combination with C5 Complement Blockade for Refractory MG

Dual targeting of FcRn (FCGRT, Open Targets score 0.59) and complement C5 (score 0.57) addresses both pathogenic antibody recycling and complement-mediated neuromuscular junction damage. ChEMBL compounds CHEMBL508564 and CHEMBL508411 target FCGRT, while existing drugs like eculizumab target C5.
openaire   +3 more sources

Viral infections and related fatal adverse events associated with complement inhibitors for PNH: a real-world pharmacovigilance analysis in FAERS

Frontiers in Pharmacology
BackgroundComplement inhibitors are increasingly utilized across various clinical indications, including the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Jinman Zhong, Chang Chen, Yunman Xu, Yueping He, Jiewen Tan, Dan Xiong   +5 more
doaj   +1 more source

Crovalimab: A Novel Approach in the Management of Paroxysmal Nocturnal Hemoglobinuria

Health Science Reports
Background and Aims Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired clonal blood disorder caused by mutations in the PIGA gene, leading to complement‐mediated hemolysis.
Laiba Jalal, Marium Ahmed, Anum Khalid
doaj   +1 more source

Human in vitro neuromuscular junction model to functionally dissect the pathogenic mechanism of anti-AChR autoantibody-positive myasthenia gravis

BMC Pharmacology and Toxicology
Background Myasthenia gravis is a rare autoimmune disease mediated by autoantibodies directed against acetylcholine receptors (AChRs) at the neuromuscular junction.
Baehyun Shin, Monica Wang, John Yim, Elisa Kwon, Margaret H. Magdesian, Camil E. Sayegh, Jason E. Ekert, Douangsone D. Vadysirisack   +7 more
doaj   +1 more source

Complement Activation and Inhibition in Wound Healing

Clinical and Developmental Immunology, 2012
Complement activation is needed to restore tissue injury; however, inappropriate activation of complement, as seen in chronic wounds can cause cell death and enhance inflammation, thus contributing to further injury and impaired wound healing. Therefore,
Gwendolyn Cazander, Gerrolt N. Jukema, Peter H. Nibbering   +2 more
doaj   +1 more source

Studies on the role of inflammation and stem cells in cardiac ischaemic injury [PDF]

, 2008
The regenerative capacity of human myocardium is unable to compensate adequately forth significant loss of heart muscle that occurs in acute myocardial infarction (Ml).
Ahmed, Ishtiaq M., Ahmed, Ishtiaq M
core  

Complement associated pathogenic mechanisms in myasthenia gravis

, 2013
The complement system is profoundly involved in the pathogenesis of acetylcholine receptor (AChR) antibody (Ab) related myasthenia gravis (MG) and its animal model experimental autoimmune myasthenia gravis (EAMG).
CHRISTADOSS, Premkumar, Erdem Tüzün, Premkumar Christadoss, Tuzun, Erdem   +3 more
core   +1 more source

Eculizumab in C3 Glomerulopathy: A Systematic Review of Therapeutic Efficacy and Clinical Outcomes

Pharmaceutics
Background: C3 glomerulopathies (C3G), including dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), are rare kidney disorders driven by dysregulation of the alternative complement pathway.
Dominik Lewandowski, Mateusz Konieczny, Krzysztof Chrzanowski, Marta Jakubowska, Zuzanna Paryzek, Miłosz Miedziaszczyk, Ilona Idasiak-Piechocka   +6 more
doaj   +1 more source